

## **Neuroimaging of hypothalamic mechanisms related to glucose metabolism in anorexia nervosa and obesity**

Joe J. Simon, Ph.D.<sup>1,2</sup>; Marion A. Stopyra, M.Sc.<sup>1</sup>; Esther Mönning<sup>1</sup>; Sebastian Sailer<sup>1</sup>; Nora Lavandier<sup>1</sup>; Lars P. Kihm, M.D.<sup>3</sup>; Martin Bendszus, M.D.<sup>4</sup>; Hubert Preissl, Ph.D.<sup>5</sup>; Wolfgang Herzog, M.D.<sup>1</sup>; Hans-Christoph Friederich, M.D.<sup>1,2</sup>

### **Affiliations:**

<sup>1</sup>Department of General Internal Medicine and Psychosomatics, Centre for Psychosocial Medicine, University Hospital Heidelberg, Heidelberg, Germany

<sup>2</sup>Department of Psychosomatic Medicine and Psychotherapy, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.

<sup>3</sup>Department of Internal Medicine I, Endocrinology and Nephrology, University Hospital of Heidelberg, Heidelberg, Germany.

<sup>4</sup>Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany

<sup>5</sup>Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen; German Center for Diabetes Research (DZD e.V.); Internal Medicine VI; Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany; Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München; German Research Center for Environmental Health (GmbH), Neuherberg, Germany

### **Corresponding author address:**

Hans-Christoph Friederich, M.D.

Centre for Psychosocial Medicine, General Internal Medicine and Psychosomatics,  
University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg

Tel.: +49 (0)6221 56-8649

Fax: +49 (0)6221 56-5749

[Hans-Christoph.Friederich@med.uni-heidelberg.de](mailto:Hans-Christoph.Friederich@med.uni-heidelberg.de)

**Conflict of interest statement:** The authors have declared that no conflict of interest exists.

## Abstract

**Background.** Given the heightened tolerance to self-starvation in anorexia nervosa, a hypothalamic dysregulation of energy and glucose homeostasis has been hypothesized. Therefore, we investigated whether hypothalamic reactivity to glucose metabolism is impaired in AN.

**Methods.** Twenty-four participants with AN, 28 normal-weight and 24 healthy participants with obesity underwent 2 magnetic resonance imaging (MRI) sessions in a single-blind, random-order, case-controlled crossover design. We used an intragastric infusion of glucose and water to bypass the cephalic phase of food intake. The responsivity of the hypothalamus and the crosstalk of the hypothalamus with reward-related brain regions were investigated using high-resolution MRI.

**Results.** Normal-weight control participants displayed the expected glucose-induced deactivation of hypothalamic activation, whereas patients with AN and participants with obesity showed blunted hypothalamic reactivity. Furthermore, patients with AN displayed blunted reactivity in the nucleus accumbens and amygdala. Compared to normal-weight and controls with obesity, patients with AN failed to show functional connectivity between the hypothalamus and reward-related brain regions during water relative to glucose. Finally, patients with AN displayed typical baseline levels of peripheral appetite hormones during a negative energy balance.

**Conclusion.** These results indicate that blunted hypothalamic glucose reactivity might be related to the pathophysiology of AN. This provides new insights for future research, as it is an extended perspective of the traditional primary nonhomeostatic understanding of the disease.

**Funding.** This study was supported by a grant from the DFG (SI 2087/2-1).

## Introduction

A fundamental question in anorexia nervosa (AN) research is to understand how patients resist food intake despite life-threatening underweight(1). Previous neuroscientific research has primarily focused on food-cue presentation and taste perception paradigms, assessing mainly nonhomeostatic factors related to the pathophysiology of AN. It has been argued that an overactive cognitive control network combined with alterations in reward, emotional and interoceptive information processing contribute to decreased food intake and heightened tolerance to physical hunger in AN(2). However, the impact of homeostatic mechanisms, including their crosstalk with nonhomeostatic factors in the development and maintenance of AN, remain largely unknown(3). In contrast to individuals with constitutional thinness, patients with AN show typical physiological adaptations to a negative energy balance in peripheral hunger and satiety hormones(4). Nonetheless, these metabolic signals do not result in adaptive strategies for regaining a neutral or positive energy balance(5). Therefore, these adaptations are thought to contribute to the maintenance of AN, given their influence over neuronal networks related to food processing(6). Similarly, abnormalities in hormonal satiety signalling is considered a hallmark feature in the aetiology of obesity, where the hypothalamus becomes less sensitive to peripheral anorexigenic as well as orexigenic signalling, leading to increased food intake(7). Furthermore, previous imaging studies have demonstrated that hyper-responsivity of the reward system to food stimuli is a risk factor for non-homeostatic eating, which has been associated with the development and maintenance of obesity(8). However, gut-brain signalling and homeostatic glucose processing in adult obesity is largely unexplored, with only a few studies investigating the hypothalamic response to oral glucose ingestion(9, 10).

The hypothalamus and brainstem regions are crucial in monitoring energy balance through a number of hormonal and neural nutrient-sensing mechanisms, thus allowing an accurate and stable energy and body weight regulation(11). Gastric peptides interact with the mesocorticolimbic reward circuitry via the hypothalamus to modulate rewarding aspects of food intake(12). Specifically, the nucleus accumbens (NAcc) is instrumental in encoding the reinforcing value of food, a process that has been found to be partially regulated via glucose metabolism (13, 14). Similarly, the amygdala has previously been associated with anticipatory food reward processing (15) and activity levels in this region have been found to be influenced by hormonal satiety signaling (16). The lateral hypothalamus and brainstem regions have subgroups of neurons that are specifically responsible for sensing and regulating glucose levels(17). Previous studies found that the hypothalamus responds with decreased activity upon administration of glucose(18, 19). However, the investigation of in vivo hypothalamic responses to nutrient ingestion using functional MRI (fMRI) is challenging. At present, the extent to which the hypothalamus as the core region for homeostatic regulation is involved in the pathophysiology of AN patients remains largely unknown(20).

In the present study, a high-resolution fMRI with an optimized protocol for the hypothalamus and mesocorticolimbic reward system was employed to investigate the small-sized hypothalamus localized around the third ventricle. Furthermore, a single-blind, randomized crossover design of an intragastric infusion of glucose and water was used to bypass the cephalic phase of food intake (i.e., sight, smell, taste). Including a normal-weight and obese control group allowed us to differentiate hypothalamic reactivity to glucose across a wide range of Body-Mass-Indexes. Taken together, the aim of this study was to gain new and valuable insights into the

glucose-induced hypothalamic reactivity as well as the crosstalk between the hypothalamus and the mesocorticolimbic reward network in patients with AN.

## Results

### ***Behavioral and Subject Data.***

Demographic and Clinical Characteristics of Participants are given in Table 1. Two normal-weight and one obese control participants had to be excluded due to technical difficulties or excessive head movement during scanning (Figure 1). Participants remained unaware of the type of liquid administered during each session, since all three groups guessed at chance level at the first (healthy controls:  $\chi^2=0.465$ ,  $P=0.495$ , AN:  $\chi^2=0.621$ ,  $P=0.431$ , controls with obesity:  $\chi^2=0.168$ ,  $P=0.682$ ) and second visit (healthy controls:  $\chi^2=2.707$ ,  $P=0.1$ , AN:  $\chi^2=1.731$ ,  $P=0.188$ , controls with obesity:  $\chi^2=0.011$ ,  $P=0.916$ ). All participants rated their subjective sensation of hunger before and after each session. A repeated-measures ANOVA with liquid type (infusion of water or glucose) and time point (before or after infusion of water/glucose) as within-subject factors and group as a between-subject factor revealed an effect of liquid type on hunger ratings ( $P=0.026$ ) but no effect of time point ( $P=0.287$ ). There was no interaction between group and liquid type ( $P=0.293$ ), but there was a significant interaction between group and time point ( $P=0.047$ ). Post hoc tests revealed that both normal-weight controls as well as patients with AN failed to show differences in hunger ratings before and after each session (normal-weight controls, all  $P_s>0.059$ , patients with AN, all  $P_s>0.117$ ). However, controls with obesity showed an increase in hunger ratings after the infusion of water:  $P=0.007$ . When comparing pre-post differences in hunger ratings between groups, we observed no differences between normal-weight controls and patients with AN ( $P_s>0.06$ ) or between overweight controls and patients with AN ( $P_s>0.352$ ).

### ***Hormonal Satiety Parameters.***

Due to technical difficulties, blood samples were not collected for all participants, and the respective group sizes are given in Table 2. As expected, patients with AN showed typical hormonal adaptations to a negative energy balance with decreased blood plasma leptin and insulin and increased serum active ghrelin levels. Taken together, although we observed some differences between groups in base-line or post-infusion levels, the infusion of glucose increased blood glucose and insulin levels and decreased active ghrelin levels in comparable proportions in all three groups (detailed results are given in Table 2).

### ***Structural brain differences.***

Hypothalamic volumetric differences between groups are detailed in the supplementary materials. In short, there was no difference in hypothalamic volume (calculated as a percentage of total brain volume) between normal-weight control participants and patients with AN, but increased hypothalamic volume in normal-weight control participants when compared to controls with obesity. However, there was no difference in hypothalamic volume between patients with AN and controls with obesity.

### ***Glucose and water induced BOLD activation in homeostatic and reward-related brain regions.***

Normal-weight control participants showed the expected glucose-induced attenuation of hypothalamic activity: a comparison of the area under the curve (AUC) revealed significant differences between glucose / water infusion ( $t_{27}=3.58$ ,  $P=0.001$ ).

However, glucose ingestion in patients with AN and controls with obesity failed to reduce hypothalamic activity (AN:  $t_{23}=1.98$ ,  $P=0.059$ , controls with obesity:  $t_{23}=0.741$ ,  $P=0.465$ , Figure 2). A group comparison revealed significant differences between all



three groups in BOLD signal response in the hypothalamus during glucose infusion ( $F_{2,73}=5.74$ ,  $P=0.005$ , Figure 5), with a stronger deactivation in normal-weight controls when compared to AN ( $t_{50}=2.52$ ,  $P=0.015$ ) and when compared to controls with obesity ( $t_{50}=2.75$ ,  $P=0.008$ ), but no significant difference between controls with obesity and AN ( $P=0.911$ ). We failed to observe any significant correlation between signal response in the hypothalamus and hormonal satiety parameters in the whole group ( $P_s>0.169$ ) as well as in normal-weight controls ( $P_s>0.06$ ), patients with AN ( $P_s>0.129$ ) and controls with obesity ( $P_s>0.418$ ).

Furthermore, activation in the nucleus accumbens and amygdala was attenuated by glucose ingestion in normal-weight controls, but not in the AN and controls with obesity groups (see Figures 3, 4 and 5 for detailed results). A group comparison revealed significant differences between groups in BOLD signal response in the nucleus accumbens during glucose infusion and in the amygdala. Furthermore, we analyzed activation in the caudate nucleus (the dorsal part of the striatum), putamen (encompassing most of the ventral part of the striatum), insular cortex, medial orbitofrontal cortex and inferior operculum (corresponding to the primary gustatory cortex). We found a significant deactivation in all regions of interest in normal-weight controls, but no significant deactivation in any of the regions in control participants with obesity and patients with AN. We observed significant group differences for the caudate nucleus, putamen and insular cortex, but no group differences for the medial orbitofrontal cortex and inferior operculum. Post-hoc tests revealed no significant differences between normal-weight control participants and patients with AN in BOLD signal response in the caudate nucleus, putamen and insular cortex. Detailed results are given in the supplementary materials.

***Satiety-state dependent functional connectivity from the hypothalamus to reward-related brain regions.***

Normal-weight controls and participants with obesity displayed increased functional connectivity from the hypothalamus to reward-related brain regions after water infusion when compared to glucose (ventral striatum, medial orbitofrontal cortex, insula,  $P < 0.05$  significance threshold, family-wise error [FWE] whole-brain corrected, see supplementary Figure 3). Participants with obesity displayed increased functional connectivity in the primary gustatory cortex after the infusion of glucose. In patients with AN, a reduced connectivity profile was observed with only the posterior insula showing increased connectivity after water infusion with the hypothalamus (supplementary Figure 3). Analysis of group differences revealed differences between normal-weight controls and patients with AN in functional connectivity between the hypothalamus and left ventral striatum and differences between normal-weight controls and participants with obesity in functional connectivity between the hypothalamus and brainstem. Furthermore, we also observed differences between patients with AN and controls with obesity in functional connectivity between the hypothalamus and left ventral striatum (see Figure 6). Supplementary tables 1 & 2 provide additional clusters of activation emerging from the within- and between groups analyses.

## Discussion

This study investigated glucose-induced hypothalamic reactivity in patients with AN in comparison to both normal-weight and controls with obesity. Employing a single-blind nasogastric infusion of glucose and water, we found that compared to normal-weight controls, patients with AN and participants with obesity showed diminished responses in the hypothalamus, ventral striatum and amygdala following glucose infusion.

Furthermore, healthy controls and participants with obesity showed satiety-state-dependent connectivity between the hypothalamus and mesocorticolimbic reward circuitry, whereas patients with AN did not. To our knowledge, this is the first brain imaging study directly comparing participants with normal-weight, obesity and anorexia nervosa in response to glucose-induced hypothalamic reactivity.

In recent decades, neurobiological research delivered new insights in the mechanisms of metabolic and hormonal gut-brain signaling(21, 22). In particular, experimental research in animals has led to a profound understanding of the major factors that determine homeostatic and energy balance regulation(23). Under a negative energy balance, a number of adaptive strategies for regaining a neutral or positive energy balance are triggered via the gut-brain axis. There is a plethora of evidence linking hypothalamic dysregulation to the development and progression of obesity(24), where neural inflammation in the hypothalamus causes alterations in hypothalamic circuitry and outputs to other brain areas(25). On the other hand, an involvement of hypothalamic dysregulation in the pathophysiology of self-starvation in AN has just recently met a growing research interest(26, 27). Our observation of blunted hypothalamic reactivity to intragastral infusion of glucose supports a pivotal role of hypothalamic dysfunction in AN and is in line with previous reports of a central nervous resistance to hormonal satiety in AN(28). Importantly, since both AN and controls with obesity groups displayed similar glucose-induced changes in hormonal

signaling when compared to normal-weight controls (i.e. an increase in insulin and blood glucose, but a decrease in ghrelin values), the observed blunted hypothalamic reactivity is less likely to be triggered by differences in the peripheral metabolism of glucose. Therefore, our results point towards a diminished central neuronal reaction to glucose metabolism in obesity and AN.

However, patients with AN differed from controls with obesity in the crosstalk between the hypothalamus and the reward system. During glucose infusion, controls with obesity showed increased connectivity, whereas patients with AN showed decreased connectivity with brain regions involved in reward processing. In patients with AN, an impaired crosstalk between the hypothalamus and the mesocorticolimbic reward system may lead to a partial or even complete loss of the hypothalamic regulation of food intake. Homeostatic hunger is known to increase brain activation in the reward system in response to exteroceptive food cues(29, 30), which further corroborates the close interaction between the hypothalamus and the neural reward network(14). Therefore, our result indicate that gut-brain signaling in AN is characterized by a blunted hypothalamic reactivity and concurrent reduced coding of hedonic and motivational aspects of food. Furthermore, our findings suggest that patients with AN have difficulties in differentiating between physical hunger and satiety, and depend to a greater extent on the cephalic phase (i.e. sight, smell, taste) to regulate their food intake. This lack of homeostatic regulation may allow patients with AN to tolerate physical hunger up to life-threatening underweight. Our results are in support of and extend the long held assumption of reduced food reward processing as a core neural mechanism underlying the development of AN(31). The blunted hypothalamic reactivity and reduced connectivity with brain reward regions pinpoint towards an inhibition of intuitive motivational responses to food stimuli(2, 32).

However, reduced hypothalamic reactivity to glucose infusion in obesity seems to be associated with an increased hedonic reactivity independent and decoupled from homeostatic signalling. This is in line with previous reports, where an exaggerated neural reactivity of the reward network in response to high-caloric visual food cues and stronger functional connections between reward areas and the medial hypothalamus were observed in participants with obesity(33, 34). Taken together, our results corroborate the assumption that a hyper-responsive reward system predominates the homeostatic regulation of food intake in obesity(35), potentially promoting overconsumption of high caloric food via increased motivational importance of food stimuli(36).

### ***Limitations***

Our study has several limitations. Since participants were given an infusion of glucose, we were unable to assess the effects of macronutrients on gut-brain signaling. Furthermore, future studies should assess trait and state aspects of impaired homeostatic signaling by including participants at risk of or recovered from AN or obesity. Since we included only female participants in our study, the observed results should be generalized to men with caution. Additionally, we did not control for the menstrual cycle in this study, which is a potential confounding factor since it has previously been shown that neural food processing in women is influenced by the menstrual cycle(37). Moreover, since the hypothalamus is involved in the regulation of thirst(38) and has been associated with the development of dehydration-induced anorexia(39), the influence of dehydration on hypothalamic reactivity in AN should be explored in further studies. Although we employed an fMRI acquisition procedure tailored to the small hypothalamic volume, its proximity to the sphenoid sinus makes the resulting images susceptible to inhomogeneities in the local magnetic field.

Together with the fact that the hypothalamus is composed of nuclei with partially different functional properties, the method of fMRI may only partially be able to assess this region. Additionally, the interaction between peripheral signals of energy homeostasis and neural reactivity is complex and remains only partially understood(40). Opposite the well-established response of the hypothalamus to glucose administration is the uncertainty regarding the exact mechanisms underlying this reaction (41). Taken together, further research is necessary to replicate these preliminary findings and to study in more detail the influence of satiety states on the hypothalamus and on the interaction of the hypothalamus with the mesocorticolimbic reward system in AN.

### ***Conclusions***

The etiology and pathogenesis of anorexia nervosa is still largely unknown. By circumventing the cephalic phase of food consumption, the present study may support new paths in research by offering a role of altered reactivity in the pathophysiology of AN. By investigating the neural correlates of homeostatic regulation across the BMI-spectrum in different satiety states, this study provides a better understanding of gut-brain signalling in human eating behaviour. The findings suggest that in addition to excessive self-regulatory control of food intake, blunted reactivity in the hypothalamus, nucleus accumbens and amygdala may perpetuate self-starvation behaviors in AN. This is in line with current genome-wide-association studies indicating fundamental metabolic dysregulation as a trait marker in AN(42). In addition to studies focusing primarily on nonhomeostatic neural mechanisms of food intake, further research is needed to understand alterations in the homeostatic regulation of food intake in AN.

## **Methods**

### ***Participants***

We included 24 patients with AN and 30 normal-weight as well as 25 controls with obesity. All participants were female. Patients with anorexia nervosa (AN) were recruited consecutively from our in- and out-patient department after giving their written informed consent. Patients had to meet the diagnostic criteria for AN (DSM-IV criteria) and have a body mass index (BMI) below  $17.5\text{kg/m}^2$  and above  $13\text{kg/m}^2$ . Normal-weight controls had a BMI below  $25\text{kg/m}^2$  but higher than  $18.5\text{kg/m}^2$  and no lifetime or current medical illness that could potentially affect appetite or weight. Control participants with obesity had a BMI between  $30\text{kg/m}^2$  and  $45\text{kg/m}^2$  and no lifetime or current medical illness that could potentially affect appetite or weight (including eating disorders diagnosis). Exclusion criteria were history of head injury or operation, neurological disorder, psychosis, bipolar disorder, current or lifetime substance abuse, or borderline personality disorder; the current use of psychotropic medications, except SSRIs (four patients with AN were currently taking SSRI medications; none of the participants from both control groups were taking psychotropic medications). Normal-weight control participants were matched to patients with AN and control participants with obesity regarding age and education level. However, there was a significant age difference between patients with AN and control participants with obesity (Table 1). In the AN group, 17 participants were diagnosed with restricting-type AN and 7 with binge/purging-type AN.

### ***Procedures***

We employed a randomized, single-blind, crossover experimental fMRI design of intragastric glucose vs. water infusion via a nasogastric tube. All sessions took place at the same time of the day (12:00P.M.) with a one-week gap between the two

sessions. All participants were asked to fast overnight (no food or caloric beverages later than 08:00P.M.). Immediately before and after the fMRI scanning, participants performed hunger and mood ratings. A nasogastric tube for liquid administration was positioned at least 60min before entering the scanner. A fine-bore nasogastric feeding tube (Flocare Nutrisoft, Nutricia GmbH, Erlangen) was positioned with its tip in the stomach 5cm below the xiphoid process and fixed with adhesive tape to the subject's face. Accurate positioning was verified by aspirating gastric contents. Participants then received either 75g of glucose dissolved in 300ml of water or an equivalent amount of water (300ml) without glucose. Injection of fluids took a maximum of 2min.

Blood samples were obtained at two time points: 30min before liquid ingestion and 45min after liquid ingestion, to determine the participants' plasma glucose, insulin, and ghrelin concentrations (see below). This time frame was chosen to obtain estimates of hormonal satiety parameters in close temporal alignment with our fMRI sequence and because blood glucose values are expected to peak after a period of roughly 30 to 45min following the ingestion of 75g of glucose(43). Liquids were administered from the experimenter after a 5min baseline scan. To ensure concealment of the liquid type, the syringes used for the application were wrapped with tape. Following injection, participants were scanned for 30min to assess brain-related activity during the digestion of glucose or water. Following this, an experimental food cue reactivity task lasting 15min was performed, and the results of the latter are reported elsewhere(44, 45). After leaving the scanner, the nasogastric tube was removed; 10ml of water was injected in the feeding tube prior to removal to prevent oral detection of the liquid type. The feasibility of the procedure and blinding was successfully validated prior to the application.

### ***Blood sampling***



Two blood samples were collected 30min before liquid infusion and 45 min after infusion for the measurement of peripheral glucose, insulin, and total and active acyl-ghrelin. Blood samples were collected using Multify needles (21G, Sarstedt AG & Co, Nümbrecht) and kept on ice in chilled tubes containing EDTA-2Na and serine protease inhibitor (for ghrelin measurement, Pefabloc SC, Sigma-Aldrich, USA). Blood samples were then centrifuged at 2000 g for 15 min and stored at -80°C for later measurement. For the measurement of total and active ghrelin, the plasma tubes were acidified with HCl to a final concentration of 0.05 N to preserve the integrity of the ghrelin. The plasma glucose concentration was measured using the glucose oxidase method (Merck KGA, Darmstadt). Plasma insulin and total and active ghrelin were measured using commercially available kits from Merck Millipore (Merck KGA, Darmstadt). HOMA-IR was obtained by multiplying the insulin concentration with by the glucose concentration and dividing the result by 405.

### ***fMRI Acquisition***

Functional imaging was performed on a 3-Tesla Tim Trio Scanner (Siemens Medical, Erlangen, Germany) scanner using a 32-channel head coil. A high-resolution gradient-recalled EPI acquisition following the sequence parameter sets previously used in other groups was employed(46, 47). Thirty-five axial slices centered at the hypothalamus and aligned along the AC-PC line were acquired with a slice thickness of 2mm and no gap. The field of view was 10.4cmx10.4cm with a matrix size of 52x52 and a flip angle of 80°. This high spatial resolution acquisition scheme significantly reduces signal drop-out in the amygdala-hypothalamus region(48). Parallel imaging with a GRAPPA factor of two was used to enable both a TE of 30ms and a TR of 2260ms at this high spatial resolution. The field of view of the employed high-resolution EPI sequence provided reduced brain coverage, with regions located

dorsally from the corpus callosum left out, see supplementary Figure 2 for a depiction of the mean EPI brain coverage and resulting 2nd-level mask used for group comparison in the connectivity analysis. Additionally, a T1-weighted high-resolution anatomical image with 192 slices (1x1x1mm voxel size, TR = 1900ms, TE = 2.52ms, flip angle = 9°, field of view = 25.6cmx25.6cm) was acquired for anatomical reference.

### ***Statistical Analysis***

**Region-of-interest based MRI analysis.** To assess hypothalamic activity, the hypothalamus of each individual was manually segmented and pre-infusion and post-infusion scans were divided into 14 consecutive 2min time bins. For each subject and each condition (glucose, water), the signal averages within the hypothalamus region-of-interest (ROI) during the 13 post-infusion time bins were compared with the baseline average. After motion correction of fMRI images by realignment to the mean image, the hypothalamus of each individual was manually segmented in a single-blind fashion using the respective anatomical image in native space following predefined criteria(9), supplementary Figure 1. Additional reward-related brain regions (nucleus accumbens, amygdala) were automatically segmented from individual brain scans using FreeSurfer (<http://surfer.nmr.mgh.harvard.edu>).

Furthermore, a reference region of about the same size as the hypothalamus ROI was drawn in the occipital cortex of each individual. The mean signal of this reference area was subtracted from that in the hypothalamus to correct for global signal drift.

To assess differences between conditions and groups, we compared the area under the curve (AUC), calculated using the trapezoidal rule by approximating the region under the graph. AUC values were compared using a repeated measures ANOVA and post-hoc tests were performed using two-sample t-tests. To assess structural

brain differences between groups, we calculated the hypothalamic volume (as a percentage of total brain volume) as well as volume of the total gray- and white matter for each participant, and compared the mean volume of each group using an independent-sample t-test. The relation between hypothalamic activity and hormonal satiety parameters was assessed using the Pearson product-moment correlation coefficient (2 tailed,  $P < 0.05$ ).

**Seed-Based Connectivity Analysis.** A whole-brain connectivity analysis as implemented in the CONN toolbox (v17; <https://www.nitrc.org/projects/conn>; 50), was performed to assess functional coupling between the hypothalamus and the rest of the brain (i.e. voxels contained within the reduced brain mask, see supplementary Figure 2) in response to glucose/water infusion. fMRI data were preprocessed using SPM8-based routines (<http://www.fil.ion.ucl.ac.uk/spm/software/spm8/>). To account for magnetic field equilibration, four volumes from the start of each functional run were excluded from the analysis. All functional images were inspected manually for artifacts. Functional scans were slice-time corrected with reference to the first slice using SPM8's Fourier phase-shift interpolation. Images were then realigned, with the allowed motion limited to  $\pm 4$ mm translation and  $\pm 3^\circ$  of rotation over the entire experiment. One normal-weight control had to be excluded due to excessive head movement during scanning; one normal-weight control and one control with obesity had to be excluded due to technical difficulties during scanning. Furthermore, the "Artifact Detection Tools" toolbox ([http://www.nitrc.org/projects/artifact\\_detect](http://www.nitrc.org/projects/artifact_detect)) was used for outlier detection, and single scans identified as invalid outliers were removed from subsequent analysis. Individual T1 images were coregistered with the mean T2\* images and subsequently segmented into gray matter (GM), white matter (WM), and cerebrospinal fluid (CSF) partitions and were spatially normalized to the Montreal Neurological Institute (MNI) standardized space (<http://www.mni.mcgill.ca/>). The

functional volumes were resampled to a  $1 \times 1 \times 1\text{mm}^3$  voxel size and spatially smoothed with an 8mm full-width half-maximum (FWHM) isotropic Gaussian kernel. In the subsequent seed-to-voxel analysis, the temporal correlation between the BOLD signal from the hypothalamus seed to all other voxels in the brain was computed. Head motion measured in 6 dimensions was included as a nuisance variable; furthermore, a component-based noise reduction method (CompCor(51)) removed principal components based on both white matter and CSF signals and accounted for physiological noise, such as heart rate and respiration. We then used the individually segmented masks of the hypothalamus as seed masks at the individual level. Time series of each condition were extracted from each voxel within the region of interest in native space. Specifically, we used the realigned fMRI data stemming from the time-series analysis to extract region of interest data. This allowed us to extract BOLD data in the original native space of each participant, thereby increasing spatial fidelity. Block regressors corresponding to the 14 consecutive 2-min time bins were convolved with a canonical hemodynamic response function and subsequently temporally bandpass filtered ( $0.008 < f < 0.09$ ) to remove low-frequency drift and high-frequency noise. For each participant, bivariate Pearson correlation analyses were performed to estimate the connection from the seed hypothalamus ROI to other voxels in the brain using the preprocessed (i.e., normalized and smoothed data) fMRI data. The resulting statistical maps were analyzed in a random-effects group analysis to compare connectivity profiles between groups. Specifically, we performed a repeated-measures ANOVA with liquid type and time point as within-subject factors and group as a between-subject factor. Age as well as depression scores (as assessed by the “Beck Depression Inventory II”) were included as covariates of no interest for between-group analyses. Whole-brain second-level results are reported for the main effect of liquid type (i.e., satiety).

Statistical inference was based on a significance threshold of  $P < 0.05$  corrected for multiple comparisons using family-wise error (FWE) correction for small volumes and a cluster-defining threshold of  $k > 30$  voxel minimal cluster size. Post hoc analyses were performed to determine the direction of significant ANOVA results; beta-values (parameter estimates) were extracted in SPM and subsequently analyzed using paired Student's t-tests (two-tailed) for within-group results and two-sample Student's t-tests (two-tailed) for between-group results. The significance threshold was set at  $P < 0.05$ .

**Statistics Overview.** Within group analyses of hypothalamic reactivity to glucose and water were compared using two-tailed paired Student's t-tests ( $P < 0.05$ ). Between group analyses of hypothalamic reactivity was performed using a repeated measures ANOVA with group as a between-subject factor and post-hoc two-sample two-tailed Student's t-tests ( $P < 0.05$ ). A random-effects group analysis using a repeated-measures ANOVA with group as a between-subject factor was used for the seed-based connectivity analysis, age and depression scores were included as covariates of no interest for between-group analyses. Results were deemed significant at  $P < 0.05$  corrected for multiple comparisons using family-wise error (FWE) correction for small volumes and a cluster-defining threshold of  $k > 30$  voxel minimal cluster size. Beta-values were analysed using paired Student's t-tests (two-tailed) for within-group results and two-sample Student's t-tests (two-tailed) for between-group results. The significance threshold was set at  $P < 0.05$ . Behavioural data was analysed using a chi-square Pearson test for independence (guess of liquid type,  $P < 0.05$ ) and repeated-measures ANOVA with group as between factor and post-hoc two-sample two-tailed Student's t-tests (hunger ratings,  $P < 0.05$ ). Hormonal Satiety Parameters were analysed using a repeated-measures ANOVA and post-hoc paired as well as two-sample Student's t-tests (two-tailed,  $P < 0.05$ ). Correlations were

performed using the Pearson product-moment correlation coefficient (2 tailed,  $P<0.05$ ).

**Study approval.** The Medical Ethics Committee of the Medical Faculty Heidelberg at the Ruprecht-Karls-University in Heidelberg, Germany, approved this study (protocol number S-373/2014) and written informed consent was obtained from all participants.

**Author Contributions:** J.J.S., M.B., H.P., L.P.K., W.H. and H-C.F. designed the research, M.S., E.M., S.S., N.L. collected the data, J.J.S., M.S. and H-C.F. analysed the data, J.J.S., M.B., H.P., L.P.K., W.H. and H-C.F. wrote the manuscript.

## References

1. Zipfel S, Giel KE, Bulik CM, Hay P, and Schmidt U. Anorexia nervosa: aetiology, assessment, and treatment. *Lancet Psychiatry*. 2015;2(12):1099-111.
2. Mayer EA. Gut feelings: the emerging biology of gut–brain communication. *Nature Reviews Neuroscience*. 2011;12(8):453-66.
3. Kaye WH, Fudge JL, and Paulus M. New insights into symptoms and neurocircuit function of anorexia nervosa. *Nature Reviews Neuroscience*. 2009;10(8):573-84.
4. Estour B, Marouani N, Sigaud T, Lang F, Fakra E, Ling Y, et al. Differentiating constitutional thinness from anorexia nervosa in DSM 5 era. *Psychoneuroendocrinology*. 2017;84:94-100.
5. Monteleone P, and Maj M. Dysfunctions of leptin, ghrelin, BDNF and endocannabinoids in eating disorders: beyond the homeostatic control of food intake. *Psychoneuroendocrinology*. 2013;38(3):312-30.
6. Frank GKW, DeGuzman MC, and Shott ME. Motivation to eat and not to eat - The psycho-biological conflict in anorexia nervosa. *Physiol Behav*. 2019;206:185-90.
7. Berthoud HR, Munzberg H, and Morrison CD. Blaming the Brain for Obesity: Integration of Hedonic and Homeostatic Mechanisms. *Gastroenterology*. 2017;152(7):1728-38.
8. Burger KS, and Berner LA. A functional neuroimaging review of obesity, appetitive hormones and ingestive behavior. *Physiol Behav*. 2014;136:121-7.
9. Matsuda M, Liu Y, Mahankali S, Pu Y, Mahankali A, Wang J, et al. Altered Hypothalamic Function in Response to Glucose Ingestion in Obese Humans. *Diabetes*. 1999;48(9):1801-6.
10. Jastreboff AM, Sinha R, Arora J, Giannini C, Kubat J, Malik S, et al. Altered Brain Response to Drinking Glucose and Fructose in Obese Adolescents. *Diabetes*. 2016;65(7):1929-39.
11. Berthoud HR. Metabolic and hedonic drives in the neural control of appetite: who is the boss? *Current Opinion in Neurobiology*. 2011;21(6):888-96.
12. Ladenheim EE. Gastrointestinal regulatory peptides and central nervous system mechanisms of weight control. *Current opinion in endocrinology, diabetes, and obesity*. 2012;19(1):13-8.
13. Baldo BA, and Kelley AE. Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding. *Psychopharmacology (Berl)*. 2007;191(3):439-59.
14. de Araujo IE, Lin T, Veldhuizen MG, and Small DM. Metabolic regulation of brain response to food cues. *Current Biology*. 2013;23(10):878-83.
15. Berridge KC. Food reward: brain substrates of wanting and liking. *Neurosci Biobehav Rev*. 1996;20(1):1-25.
16. Zanchi D, Depoorter A, Egloff L, Haller S, Mahlmann L, Lang UE, et al. The impact of gut hormones on the neural circuit of appetite and satiety: A systematic review. *Neurosci Biobehav Rev*. 2017;80:457-75.
17. Burdakov D, Luckman SM, and Verkhatsky A. Glucose-sensing neurons of the hypothalamus. *Philosophical Transactions of the Royal Society B: Biological Sciences*. 2005;360(1464):2227-35.
18. Page KA, Chan O, Arora J, Belfort-DeAguiar R, Dzuira J, Roehmholdt B, et al. Effects of fructose vs glucose on regional cerebral blood flow in brain regions involved with appetite and reward pathways. *JAMA*. 2013;309(1):63-70.


19. Smeets PA, de Graaf C, Stafleu A, van Osch MJP, and van der Grond J. Functional MRI of human hypothalamic responses following glucose ingestion. *Neuroimage*. 2005;24:363-8.
20. van Opstal AM, Westerink AM, Teeuwisse WM, van der Geest MA, van Furth EF, and van der Grond J. Hypothalamic BOLD response to glucose intake and hypothalamic volume are similar in anorexia nervosa and healthy control subjects. *Front Neurosci*. 2015;9:159.
21. Konturek SJ, Konturek JW, Pawlik T, and Brzozowski T. Brain-gut axis and its role in the control of food intake. *Journal of Physiology and Pharmacology*. 2004;55(1 Pt 2):137-54.
22. Field BC, Chaudhri OB, and Bloom SR. Bowels control brain: gut hormones and obesity. *Nature Reviews Endocrinology*. 2010;6(8):444-53.
23. Morton GJ, Cummings DE, Baskin DG, Barsh GS, and Schwartz MW. Central nervous system control of food intake and body weight. *Nature*. 2006;443(7109):289-95.
24. Timper K, and Bruning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. *Dis Model Mech*. 2017;10(6):679-89.
25. Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, et al. Obesity is associated with hypothalamic injury in rodents and humans. *The Journal of clinical investigation*. 2012;122(1):153-62.
26. Frank GK, Shott ME, Riederer J, and Pryor TL. Altered structural and effective connectivity in anorexia and bulimia nervosa in circuits that regulate energy and reward homeostasis. *Transl Psychiatry*. 2016;6(11):e932.
27. Florent V, Baroncini M, Jissendi-Tchofo P, Lopes R, Vanhoutte M, Rasika S, et al. Hypothalamic structural and functional imbalances in anorexia nervosa. *Neuroendocrinology*. 2019.
28. Miljic D, Pekic S, Djurovic M, Doknic M, Milic N, Casanueva FF, et al. Ghrelin has partial or no effect on appetite, growth hormone, prolactin, and cortisol release in patients with anorexia nervosa. *The Journal of clinical endocrinology and metabolism*. 2006;91(4):1491-5.
29. Friederich HC, Wu M, Simon JJ, and Herzog W. Neurocircuit function in eating disorders. *International Journal of Eating Disorders*. 2013;46(5):425-32.
30. Siep N, Roefs A, Roebroek A, Havermans R, Bonte ML, and Jansen A. Hunger is the best spice: An fMRI study of the effects of attention, hunger and calorie content on food reward processing in the amygdala and orbitofrontal cortex. *Behavioural Brain Research*. 2009;198(1):149-58.
31. Kaye WH, Wierenga CE, Bailer UF, Simmons AN, and Bischoff-Grethe A. Nothing tastes as good as skinny feels: the neurobiology of anorexia nervosa. *Trends in Neurosciences*. 2013;36(2):110-20.
32. Goldzak-Kunik G, Friedman R, Spitz M, Sandler L, and Leshem M. Intact sensory function in anorexia nervosa. *American Journal of Clinical Nutrition*. 2012;95(2):272-82.
33. Berthoud HR, and Morrison C. The brain, appetite, and obesity. *Annu Rev Psychol*. 2008;59:55-92.
34. Stoeckel LE, Weller RE, Cook EW, 3rd, Twieg DB, Knowlton RC, and Cox JE. Widespread reward-system activation in obese women in response to pictures of high-calorie foods. *Neuroimage*. 2008;41(2):636-47.
35. Smith DG, and Robbins TW. The neurobiological underpinnings of obesity and binge eating: a rationale for adopting the food addiction model. *Biol Psychiatry*. 2013;73(9):804-10.



36. Simon JJ, Skunde M, Hamze Sinno M, Brockmeyer T, Herpertz SC, Bendszus M, et al. Impaired Cross-Talk between Mesolimbic Food Reward Processing and Metabolic Signaling Predicts Body Mass Index. *Front Behav Neurosci.* 2014;8:359.
37. Arnoni-Bauer Y, Bick A, Raz N, Imbar T, Amos S, Agmon O, et al. Is It Me or My Hormones? Neuroendocrine Activation Profiles to Visual Food Stimuli Across the Menstrual Cycle. *J Clin Endocrinol Metab.* 2017;102(9):3406-14.
38. Bichet DG. Vasopressin and the Regulation of Thirst. *Ann Nutr Metab.* 2018;72 Suppl 2:3-7.
39. Watts AG, Sanchez-Watts G, and Kelly AB. Distinct patterns of neuropeptide gene expression in the lateral hypothalamic area and arcuate nucleus are associated with dehydration-induced anorexia. *J Neurosci.* 1999;19(14):6111-21.
40. Ferrario CR, Labouebe G, Liu S, Nieh EH, Routh VH, Xu S, et al. Homeostasis Meets Motivation in the Battle to Control Food Intake. *J Neurosci.* 2016;36(45):11469-81.
41. Bentsen MA, Mirzadeh Z, and Schwartz MW. Revisiting How the Brain Senses Glucose-And Why. *Cell Metab.* 2019;29(1):11-7.
42. Watson HJ, Yilmaz Z, Thornton LM, Hubel C, Coleman JRI, Gaspar HA, et al. Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nat Genet.* 2019;51(8):1207-14.
43. Zhou W, Gu Y, Li H, and Luo M. Assessing 1-h plasma glucose and shape of the glucose curve during oral glucose tolerance test. *Eur J Endocrinol.* 2006;155(1):191-7.
44. Stopyra MA, Friederich H-C, Sailer S, Pauen S, Bendszus M, Herzog W, et al. The effect of intestinal glucose load on neural regulation of food craving. *Nutr Neurosci.* 2019:1-10.
45. Stopyra MA, Friederich HC, Monning E, Lavandier N, Bendszus M, Herzog W, et al. The influence of homeostatic mechanisms on neural regulation of food craving in anorexia nervosa. *Psychol Med.* 2020:1-9.
46. Robinson S, Windischberger C, Rauscher A, and Moser E. Optimized 3 T EPI of the amygdalae. *Neuroimage.* 2004;22(1):203-10.
47. Karlsson KA, Windischberger C, Gerstl F, Mayr W, Siegel JM, and Moser E. Modulation of hypothalamus and amygdalar activation levels with stimulus valence. *Neuroimage.* 2010;51(1):324-8.
48. Robinson S, Pripfl J, Bauer H, and Moser E. The impact of EPI voxel size on SNR and BOLD sensitivity in the anterior medio-temporal lobe: a comparative group study of deactivation of the Default Mode. *MAGMA.* 2008;21(4):279-90.
49. McKie S, Del-Ben C, Elliott R, Williams S, del Vai N, Anderson I, et al. Neuronal effects of acute citalopram detected by pharmacofMRI. *Psychopharmacology (Berl).* 2005;180:680-6.
50. Whitfield-Gabrieli S, and Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. *Brain Connect.* 2012;2(3):125-41.
51. Behzadi Y, Restom K, Liao J, and Liu TT. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. *Neuroimage.* 2007;37(1):90-101.


## Figures

Figure 1: Study Design.




We employed a randomized, single-blind, crossover experimental fMRI design of intragastric glucose vs. water infusion via a nasogastric tube. Normal-weight control participants were matched to patients with AN and control participants with obesity regarding age and education level. Blood samples used to determine hormonal satiety parameters were obtained 30min before- and 45min after liquid ingestion.

**Figure 2:** Changes in Blood-Oxygenation-Level-Dependent (BOLD) Signal over Time in Response to Glucose and Water Ingestion in the Hypothalamus.




BOLD signal response in the hypothalamus region of interest (ROI, manually segmented on individual native space brain scans) during glucose and water infusion; a comparison of the area under the curve (AUC) revealed significant differences between conditions in healthy controls (**A**), but neither in patients with AN (**B**) nor in controls with obesity (**C**). Box-and-whisker plots, horizontal bar indicates median, box edges represent 25th and 75th percentiles, and whiskers 10th and 90th percentiles. \* $P \leq 0.05$ , \*\*  $P \leq 0.01$ , \*\*\* $P \leq 0.001$ , by paired, two-tailed Student's *t*-tests.

**Figure 3:** Changes in BOLD Signal over Time in Response to Glucose and Water Ingestion in the Nucleus Accumbens.




BOLD signal response in the nucleus accumbens ROI (automatic segmentation using FreeSurfer) during glucose and water infusion; significant differences between conditions in healthy controls (**A**,  $t_{27}=3.31$ ,  $P=0.027$ ), no significant differences in patients with AN (**B**,  $t_{23}=0.665$ ,  $P=0.512$ ) and in controls with obesity (**C**,  $t_{23}=1.94$ ,  $P=0.064$ ). Box-and-whisker plots, horizontal bar indicates median, box edges represent 25th and 75th percentiles, and whiskers 10th and 90th percentiles. \* $P\leq 0.05$ , \*\*  $P\leq 0.01$ , \*\*\* $P\leq 0.001$ , by paired, two-tailed Student's  $t$ -tests.

**Figure 4:** Changes in BOLD Signal over Time in Response to Glucose and Water Ingestion in the Amygdala.



BOLD signal response in the amygdala ROI (automatic segmentation using FreeSurfer) during glucose and water infusion; significant differences in AUC between conditions in normal-weight controls (**A**,  $t_{27}=3.54$ ,  $P=0.001$ ), no significant differences in patients with AN (**B**,  $t_{23}=0.9$ ,  $P=0.378$ ) and in controls with obesity (**C**,  $t_{23}=0.37$ ,  $P=0.71$ ). Box-and-whisker plots, horizontal bar indicates median, box edges represent 25th and 75th percentiles, and whiskers 10th and 90th percentiles. \* $P \leq 0.05$ , \*\*  $P \leq 0.01$ , \*\*\* $P \leq 0.001$ , by paired, two-tailed Student's  $t$ -tests.


**Figure 5:** Differences between groups in BOLD signal response during glucose infusion.



**A**, Group differences in hypothalamus reactivity during glucose infusion (comparison between all three groups:  $F_{2,73}=5.74$ ,  $P=0.005$ , repeated measures ANOVA). **B**, Differences between groups in BOLD signal response in the nucleus accumbens during glucose

infusion (comparison between all three groups:  $F_{2,73}=4.32$ ,  $P=0.017$ ; normal-weight controls vs. AN:  $t_{50}=2.12$ ,  $P=0.038$ ; normal-weight controls vs. controls with obesity:  $t_{50}=2.57$ ,  $P=0.013$ ; controls with obesity vs. AN:  $P=0.882$ ). **C**, Differences between groups in BOLD signal response in the nucleus accumbens during glucose infusion (comparison between all three groups ( $F_{2,73}=10.84$ ,  $P<0.001$ ; no significant differences between normal-weight controls and patients with AN,  $P=0.103$ , but significant differences between normal-weight controls and controls with obesity,  $t_{50}=-4.35$ ,  $P<0.001$ , and between controls with obesity and AN:  $t_{46}=-3.59$ ,  $P<0.001$ . Box-and-whisker plots, horizontal bar indicates median, box edges represent 25th and 75th percentiles, and whiskers 10th and 90th percentiles. \* $P\leq 0.05$ , \*\* $P\leq 0.01$ , \*\*\* $P\leq 0.001$ , by post-hoc two-sample, two-tailed Student's  $t$ -tests

**Figure 6: Satiety-State Dependent Functional Connectivity of the Hypothalamus.**





**A**, Differences between healthy controls and patients with AN in functional connectivity between the hypothalamus and left ventral striatum (glucose:  $t_{50}=-3.22$ ,  $P=0.002$ ; water:  $t_{50}=2.67$ ,  $P=0.01$ ). **B**, Differences between healthy controls and controls with obesity in functional connectivity between the hypothalamus and brainstem (glucose:  $t_{50}=3.44$ ,  $P=0.001$ ; water:  $t_{50}=-2.51$ ,  $P=0.015$ ). **C**, Differences between patients with AN and controls with obesity in functional connectivity between the hypothalamus and left ventral striatum (glucose:  $t_{46}=2.33$ ,  $P=0.024$ ; water:  $t_{46}=-2.96$ ,  $P=0.005$ ). All whole-brain results are reported at a threshold of  $P<0.05$  corrected for multiple comparisons using family-wise error (FWE) correction for small volumes and a cluster-defining threshold of  $k>30$  voxel minimal cluster size. Box-and-whisker plots, horizontal bar indicates median, box edges represent 25th and 75th percentiles, and whiskers 10th and 90th percentiles.

**Table 1. Demographic and Clinical Characteristics of Participants**

Variable	Normal-Weight Controls (N=28)	Anorexia Nervosa Group (N=24)	Participants with Obesity (N=24)	AN vs.		
				CON P Value <sup>a</sup>	OB vs. CON P Value <sup>b</sup>	OB vs. AN P Value <sup>c</sup>
Age, mean (SD), y	24.6 (4.95)	23.48 (4.95)	27.13 (5.97)	.414	.103	.007
Body mass index (SD)	21.87 (1.27)	15.48 (1.5)	35.66 (3.83)	<.001	<.001	<.001
Education, mean (SD), y	12.78 (0.78)	12.37 (1.24)	12.12 (1.39)	.155	.078	.478
BDI, mean (SD)	4.25 (3.66)	21 (14.24)	11.37 (8.16)	<.001	<.001	.009
EDEQ total score, mean (SD)	10 (9.02)	81.92 (34.46)	56.58 (21.96)	<.001	<.001	.003
EDEQ restraint, mean (SD)	2 (3.75)	18.42 (8.38)	9.95 (6.27)	<.001	<.001	<.001
EDEQ eating concern, mean (SD)	0.43 (0.69)	14.83 (7.9)	6 (4.66)	<.001	<.001	<.001
EDEQ weight concern, mean (SD)	2.46 (2.09)	17.25 (8.55)	14.33 (5.69)	<.001	<.001	.142
EDEQ shape concern, mean (SD)	5.12 (5.11)	31.42 (12.97)	26.29 (10.62)	<.001	<.001	.167

All participants are female. Abbreviations: BDI, Beck Depression Inventory; EDEQ, Eating Disorder Examination Questionnaire; CON, normal-weight controls; AN, patients with Anorexia Nervosa; OB, controls with obesity.

<sup>a</sup> The P-values presented relate to unpaired, two-sample Student's t-test comparing normal-weight controls and patients with Anorexia nervosa

---

<sup>b</sup> The P-values presented relate to unpaired, two-sample Student's t-test comparing participants with obesity and normal-weight controls

<sup>c</sup> The P-values presented relate to unpaired, two-sample Student's t-test comparing participants with obesity and patients with anorexia nervosa

**Table 2. Differences in Hormonal Satiety Parameters Before and After the Infusion of Glucose.**

Variable	Normal-Weight Controls		Anorexia Nervosa		Controls with obesity		CON vs. AN vs. OB P-value <sup>a</sup>	AN vs. CON P- value <sup>a</sup>	OB vs. AN P- value <sup>a</sup>
	Baseline	Glucose	Baseline	Glucose	Baseline	Glucose			
Blood Glucose, mg/dl	84.7±5.7	146.2±17.9***	82.4±7.9	140.1±26.3***	85±5.9	136.5±23.8***	.176	.966	.146
Insulin, mU/l <sup>b</sup>	7.8±3.2	57.5±28.9***	4.3±3.2	37.9±18.6***	14.8±7.3	102.1±64.5***	.021	.026	.012
HOMA-IR	1.9±.92		1.02±.75		3.1±1.5		<.001	.001	<.001
Leptin, µg/l	8.5±5.8		1.6±1.2		36.9±16.1		<.001	<.001	<.001
Active Ghrelin, pg/ml <sup>c</sup>	631.2±371.4	310.5±209.2***	1027.3±543.3	407.8±235.9***	410.6±305.4	182±144.4***	<.001	.017	.002

<sup>a</sup> The P-values presented relate to repeated-measures ANOVAs with time point (before and after glucose infusion) as a within factor and group as a between factor.

<sup>b</sup> Additional Post hoc tests revealed that patients with AN had different insulin baseline values than healthy controls and controls with obesity (Ps<0.002), as well as different values after infusion (Ps<0.015). Baseline-corrected differences in insulin levels before and after infusion (postinfusion levels divided by preinfusion levels) revealed no significant differences between patients with AN and healthy controls (P=0.173) but significant differences between patients with AN and controls with obesity (t39=2.25, P=0.03).

<sup>c</sup> Additional Post hoc tests revealed that patients with AN had different baseline values than healthy controls and controls with obesity (Ps<0.007), but values after infusion were different only when compared to controls with obesity (t39=2.76, P=0.009) and not when compared to healthy controls (P=0.709). Baseline-corrected differences in active ghrelin levels before and after infusion (postinfusion levels divided by preinfusion levels) revealed no significant differences between patients with AN and healthy controls (P=0.122) or between patients with AN and controls with obesity (P=0.084).

\*P≤0.05, \*\*P≤0.01, \*\*\*P≤0.001, by paired, two-tailed Student's t-tests.